PennyToBuck.com

HealthMed Services LTD., HEME.OB

By Bobbie Katz, CRWENewswire Correspondent

It’s The “Talk” of The Town

Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. Being an innovative software development company, HealthMed Services LTD (HEME.OB) has announced that it has entered into final negotiations to acquire all rights, title, and interest to Neural Communicator software and hardware.

HealthMed President/CFO John Popovic commented, “We are extremely keen on completing the acquisition of Neural Communicator. The product will bring easy communication capability to those currently unable to communicate as well as expanding the communication ability of others with disabilities restricting their communication capacity. Acquiring this leading edge technology expands HealthMed’s product lineup and will position us strongly in the marketplace.”

Neural Communicator is intended for people disabled in such a way that they cannot communicate by speech or by using their body. Biofeedback is used for computer input and controlling the application features.

For More Information On HealthMed’s “Talk” of The Town Visit: http://www.healthmedltd.com

Crown Equity Holdings Inc., CRWE.OB

Crown Equity Holdings Inc. (OTCBB:CRWE) has added a company known as PenStox.com, a German Small Cap Service Provider led by Lars Schmidt, to its CRWENewswire.com team. PenStox.com moderates the German CRWEnewswire websites in Germany and adds content to the CRWENewswire website.

Crown Equity Holdings plans to add more European companies to its CRWEnewswire network. The French site is being finalized, and is on line now at www.crwenewswire.fr. Additional sites in work are for Mexico, Taiwan and India.

Crown Equity Holdings is currently in the process of expanding its in-house IT infrastructure. Although their current web page load time is better than 75% of other internet websites, when completed, the modifications will raise this load time to better then 90% of other internet websites while increasing website visitor capacity by 400%. As CRWE adds more countries’ webswites to it’s domain, this addition of new servers and IT personnel is of great benefit.

Crown Equity Holdings Inc . is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

Please visit Crown Equity Holdings Inc’s website at: www.crownequityholdings.com

St. Jude Medical, Inc., STJ

St. Jude Medical, Inc. (NYSE:STJ) applauds the updated class and level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI) announced Monday at the European Society of Cardiology (ESC) congress in Stockholm. Supporting this change are the very strong one and two year data from the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which demonstrated improved outcomes for patients with multivessel coronary artery disease whose treatment was guided by St. Jude Medical FFR Measurement Systems rather than by standard angiography alone.

The ESC guidelines, which are intended to assist health care providers in clinical decision making, now classify FFR-guided treatment as “Class I, with level of evidence A.” Level of evidence A is the highest level available, requiring the most clinical evidence, and is awarded only when data has been derived from multiple randomized clinical trials or meta-analyses. Class I indicates a general agreement that a given treatment or procedure is beneficial, useful, and effective.

Fractional Flow Reserve (FFR) is an index determining the functional severity of narrowings in the coronary arteries as measured by PressureWire Certus and PressureWire Aeris. FFR specifically identifies which coronary narrowings are responsible for significantly obstructing the flow of blood to a patients’ heart muscle (called ischemia), and it is used by the interventional cardiologist to direct coronary interventions and assess results for improved treatment outcomes.

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide.

For more information, please visit www.sjm.com

********************************************************************

The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. (CRWE.OB) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)

HealthMed Services Ltd. (OTC:HEME), an innovative software development company, is pleased to announce that it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware. Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.

HEME has also entered into an agreement with a European Research and Development Company to develop, test and market a specialty healthcare communication product, namely Neural Vantage.

• Healthmed and its software developers are now beta testing the communicator.
• The revolutionary product will target people with disabilities such as amputation and paralysis due to the fact that these types of illnesses prevent them from communicating with ease.
• HEME has created a platform where information from the patient’s body can be entered to a computer through the use of biotechnology. This new technology is called “BCI” for Brain Computer Interface.
• The software and interface is password protected with end-to-end user authentication. All data is protected with AES encryption using 128-bit keys.
• It will automatically update of both parts of software, computer and iPad.

The software is based on plug-in architecture allowing easy implementation of new features. There are five basic modules:

• Speech module - text input for speech replacement
• GSM module - send and receive SMS
• MSN module
• Windows Live Messenger chat Book Reader - reading books by speech synthesis
• Web Browsing - special plug-ins for Bing Maps and Facebook.

HealthMed also plans to provide online services through its Web site that includes a public portal, a Web site for individuals, consumers, and the general public that is designed to provide health information and recommendations; and a private and custom-designed/client-specific portal, a private-labeled Web site that would allow employees to access their personal health records and research various health and medical related topics, as well as provide access to information and resources to assist them in making personal health plan and medical treatment decisions.

You may read more about HEME and its product developments on its website: www.healthmedltd.com

Crown Equity Holdings Inc. (OTCBB:CRWE)

CRWE release news that its sales this year have already surpassed $1,000,000.

This compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009.

Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. commented “Based on our sales to date, we had more than 4 times the sales for the same period last year and are 34% ahead of last year’s total sales.”

Mr. Bosket also stated “Our growth in sales along with our investments in infrastructure and people give the company a basis for supporting future growth of the magnitude we have seen so far this year.”

CRWE has also moved to a dedicated in-house advertising server, allowing for faster response and a wider variety of ad space offerings to those interested in advertising on their numerous internet and affiliate internet properties.

CRWE is currently in the process of expanding its in-house IT infrastructure. Although their current web page load time is better than 75% of other internet websites, when completed, the modifications will raise this load time to better then 90% of other internet websites while increasing website visitor capacity by 400%.

CRWE has expanded its internet footprint internationally to include the following 19 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Mexico, New Zealand, Singapore, Spain, Taiwan and the UK.

Cogent Communications Group, Inc. (Nasdaq:CCOI), one of the largest Internet service providers in the world, today announced that Dave Schaeffer, CCOI’s chief executive officer, will present at the following conferences:

The Kaufman Brothers 13th Annual Investor Conference is being held at The W Hotel New York in New York, NY. Dave Schaeffer will be presenting on Wednesday, September 15th at 12:30 PM ET.

The Bank of America Merrill Lynch Media, Communications and Entertainment Conference is being held at Island Hotel Newport Beach in Newport Beach, CA. Dave Schaeffer will be presenting at 10:30 AM PT on Thursday, September 16th.

Investors and other interested parties may access a live audio webcast of the conference presentations by going to the Investor Relations section of Cogent’s website (http://www.cogentco.com/us/ir_events.php) to access the link to the live audio webcasts. A replay of the Kaufman Brothers’ webcast will be available on Cogent’s IR website for 90 days following the presentation and the Bank of America Merrill Lynch webcast will be available for 14 days following the presentation.

About Cogent Communications

Cogent Communications (Nasdaq:CCOI) is a multinational, Tier 1 facilities-based ISP, consistently ranked as one of the top five networks in the world. Cogent specializes in providing businesses with high speed Internet access and point-to-point transport services. Cogent’s facilities-based, all-optical IP network backbone provides IP services in over 145 markets located in North America and Europe.

Since its inception, Cogent has unleashed the benefits of IP technology, building one of the largest and highest capacity IP networks in existence. This network enables Cogent to offer large bandwidth connections at highly competitive prices. Cogent also offers superior customer support by virtue of its end-to-end control of service delivery and network monitoring.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)

Proteonomix, Inc., (OTCBB:PROT.OB) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced on August 6, that it has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity. X Gen Medical has been established with the intention of conducting business in the global medical marketplace. Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide. It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease. StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

Herbalife Ltd. (NYSE:HLF) Chief Financial Officer John DeSimone, and Amy Greene, vice president, investor relations, will participate in the 2010 Bank of America Merrill Lynch Investment Conference on Tuesday, September 14, 2010 at 2 p.m. PDT. The audio portion of the presentation will be webcast live, and a replay will be available until Tuesday, September 28, 2010 on the investor relations section of Herbalife’s website at http://ir.herbalife.com.

Herbalife Ltd. is a global network marketing company that sells weight-management, nutrition, and personal care products intended to support a healthy lifestyle. Herbalife products are sold in 73 countries through a network of approximately 2.1 million independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains a significant amount of information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

Life Technologies Corporation (Nasdaq:LIFE), a provider of innovative life science solutions and SG Biofuels, Inc., a bioenergy crop company, recently reported that they have completed sequencing the Jatropha curcas genome to 100x coverage, using the SOLiD 4.0 System by Life Technologies. The sequence significantly accelerates the identification of key traits for the oilseed-producing crop and advances its development as a high yielding, low-cost source for next generation biofuel.

Jatropha curcas is a non-edible shrub that is native to Central America. Its seeds contain high amounts of oil that can be used for a variety of bio-based materials including feedstock substitutes for the diesel, petrochemical and jet fuel industries. It can be effectively grown on marginal lands that are considered undesirable for food crops, making it a viable option as a new biofuel.

Life Technologies Corporation is a global biotechnology tools company dedicated to improving the human condition. LIFE’s systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. LIFE customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. LIFE had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. LIFE was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

NW Tech Capital Inc., (PINK SHEETS:NWTT) recently reported that the company is currently working on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. The company management has been seeking viable businesses to vend in in North America, Asia, and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.

NWTT also recently reported that the company had finalized the merger with Bermal Contracting Ltd., a BC Canada company.

NWTT management currently works on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. NWTT’s management has been seeking viable businesses to vend in, in North America, Asia and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.

To receive additional information about NWTT, please visit the website at http://www.nwtechcapital.com

Abbott Laboratories, (NYSE:ABT)

Imagine needing a critical test at your local hospital, but having to wait days to be tested because there was no laboratory professional available to run the tests. This scene seems unimaginable, but it’s a reality in some parts of the United States, such as California.

The Abbott Fund is helping reverse this trend by supporting California’s Healthcare Laboratory Workforce Initiative (HLWI), which has helped to more than double the number of hospitals that provide on-site clinical training for aspiring laboratory science workers.

The boost in California’s lab workforce is helping to ease a serious staffing crisis. The closing of training programs at universities and hospitals, as well as aging lab technologists without an ample supply of successors, led to an average shortage of four full-time employees per hospital laboratory in the state. By helping to establish new training sites, HLWI is motivating hospitals to develop and retain their own staff. Offering training opportunities with pathways toward full-time employment lowers recruitment costs and shortens the learning curve for new workers.

To receive additional information about ABT, please visit the website at http://www.abbott.com/

Pfizer Inc. (NYSE:PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, recently announced that they have entered into an agreement under which PFE will acquire FoldRx.

FoldRx’s portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases. FoldRx’s lead product candidate, tafamidis meglumine, is in registration as an oral, disease-modifying therapy for TTR amyloid polyneuropathy , a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option that is currently available.

About Transthyretin Amyloidosis (ATTR-PN)

Transthyretin (TTR) is an amyloidogenic protein secreted by the liver. Mutations in the TTR gene have been linked to several amyloid conditions. Deposition of TTR amyloid in the peripheral nerve tissue results in transthyretin amyloid polyneuropathy (ATTR-PN), a sensory, motor and autonomic polyneuropathy. The disease usually begins in the third or fourth decade with symptoms of peripheral and/or autonomic neuropathy that inexorably progress to involve muscle strength with loss of ambulation. The patient commonly experiences a profoundly diminished quality of life with a markedly reduced life expectancy (approximately 10 years from first symptom). Liver transplantation is the only accepted treatment, but it is not uniformly effective, and is associated with significant mortality. It is estimated that ATTR-PN affects at least 8,000 patients worldwide, the majority of whom are in the European Union.

About FoldRx

FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute). Protein misfolding is increasingly being recognized as an underlying cause of many chronic degenerative diseases. By applying FoldRx’s proprietary expertise in protein folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform. FoldRx investors include Alta Partners, Fidelity Biosciences, Healthcare Ventures, Morgenthaler Ventures, Novartis Venture Funds, Novo Ventures, and TPG Biotechnology. For more information on FoldRx, please visit the company’s web site at www.foldrx.com.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (PenStox) for (15) days of advertising for NW Tech Capital, Inc. (NWTT.PK).